Femasys Inc (FEMY) - Total Assets
Based on the latest financial reports, Femasys Inc (FEMY) holds total assets worth $20.72 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See FEMY net asset value for net asset value and shareholders' equity analysis.
Femasys Inc - Total Assets Trend (2019–2025)
This chart illustrates how Femasys Inc's total assets have evolved over time, based on quarterly financial data.
Femasys Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Femasys Inc's total assets of $20.72 Million consist of 79.4% current assets and 20.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.7% |
| Accounts Receivable | $616.60K | 3.0% |
| Inventory | $5.74 Million | 27.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $134.91K | 0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Femasys Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see FEMY stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Femasys Inc's current assets represent 79.4% of total assets in 2025, an increase from 63.6% in 2019.
- Cash Position: Cash and equivalents constituted 44.7% of total assets in 2025, down from 50.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 27.7% of total assets.
Femasys Inc Competitors by Total Assets
Key competitors of Femasys Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.14 Billion |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$6.53 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Femasys Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.53 | 0.93 | 0.64 |
| Quick Ratio | 2.95 | 0.58 | 0.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.82 Million | $-560.42K | $-1.41 Million |
Femasys Inc - Advanced Valuation Insights
This section examines the relationship between Femasys Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.52 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | 66.5% |
| Total Assets | $20.72 Million |
| Market Capitalization | $23.19 Million USD |
Valuation Analysis
Above Book Valuation: The market values Femasys Inc's assets above their book value (1.12x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Femasys Inc's assets grew by 66.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Femasys Inc (2019–2025)
The table below shows the annual total assets of Femasys Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $20.72 Million | +66.53% |
| 2024-12-31 | $12.45 Million | -55.16% |
| 2023-12-31 | $27.76 Million | +64.28% |
| 2022-12-31 | $16.90 Million | -40.88% |
| 2021-12-31 | $28.58 Million | +275.70% |
| 2020-12-31 | $7.61 Million | -39.85% |
| 2019-12-31 | $12.65 Million | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornua… Read more